Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating)’s share price fell 5% during mid-day trading on Friday . The company traded as low as $55.17 and last traded at $55.36. 21,754 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,527,777 shares. The stock had previously closed at $58.29.
Analyst Ratings Changes
A number of brokerages have recently issued reports on AXSM. HC Wainwright reissued a “buy” rating and issued a $210.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, October 4th. Cowen reduced their target price on shares of Axsome Therapeutics to $125.00 in a research report on Wednesday, October 5th. SVB Leerink boosted their target price on shares of Axsome Therapeutics from $50.00 to $75.00 in a research report on Monday, August 22nd. Mizuho boosted their target price on shares of Axsome Therapeutics from $76.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Guggenheim upped their price objective on shares of Axsome Therapeutics from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.45.
Axsome Therapeutics Price Performance
The stock has a market cap of $2.56 billion, a P/E ratio of -14.53 and a beta of 1.75. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.19 and a quick ratio of 2.20. The business’s fifty day moving average price is $51.22 and its 200 day moving average price is $42.51.
Institutional Inflows and Outflows
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.